IBI110 is another anti-LAG3 that is being investigated in a phase I/II study in combination with sintilimab (anti-PD-1) in patients with ES-SCLC solid tumors, and early data of this study report that IBI110 has an acceptable safety profile and promising antitumor activity (NCT05026593) [151]. The gene discussed is LAG3; the disease is small cell lung carcinoma.